Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,000 people get OSIR articles and Market Currents by email alert.
Get email alerts on OSIR »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
Osiris Therapeutics: Still The Best Bet In Regenerative MedicineScience-Of-Aging • Tue, Nov 27, 2012 -
-
-
-
-
Sirus XM: Year In Review And 2012 OutlookPragmatic Bear • Wed, Dec 28, 2011 -
-
Expiration Trade Behind Osiris ActivityoptionMONSTER • Fri, Nov 20, 2009 -
Optimistic on Osiris TherapeuticsZacks Investment Research • Fri, May 8, 2009 -
-
Osiris: Positive Heart Drug Data Boosts StockHerb Greenberg • Tue, Mar 27, 2007
-
Osiris: Knee Replacement Drug A BustHerb Greenberg • Tue, Feb 13, 2007
-
Osiris: Good News (But A Few People Died)Herb Greenberg • Wed, Dec 13, 2006
To learn more about Seeking Alpha Pro, click here.
-
Osiris Therapeutics, Inc. Q1 2010 Earnings Call TranscriptFri, May 7, 2010
-
Osiris Therapeutics, Inc. Q4 2008 Earnings Call TranscriptFri, Feb 27, 2009
-
Osiris Therapeutics, Inc. Q1 2008 Earnings Call TranscriptFri, May 30, 2008
-
Osiris Therapeutics, Inc. Q4 2007 Earnings Call TranscriptThu, Feb 28, 2008
-
Osiris Therapeutics, Inc Q3 2007 Earnings Call TranscriptTue, Nov 13, 2007
-
Business Wire (May 30, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Mar 14, 2013)
-
at MarketWatch.com (Mar 6, 2013)
-
Business Wire (Mar 6, 2013)
-
Business Wire (Mar 1, 2013)
-
Business Wire (Feb 22, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 18, 2013)
-
Business Wire (Nov 20, 2012)
-
Business Wire (Nov 5, 2012)
-
Business Wire (Oct 29, 2012)
-
Business Wire (Oct 22, 2012)
-
Business Wire (Sep 28, 2012)
-
Business Wire (Sep 28, 2012)
-
Business Wire (Sep 20, 2012)
-
Business Wire (Sep 19, 2012)
-
Business Wire (Jul 30, 2012)
OSIR vs. ETF Alternatives
Company Description
We are a leading stem cell therapeutic company headquartered in Columbia, Maryland and focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. We were incorporated in Delaware in April 2002. Our predecessor company was... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 8:14 AM Osiris Therapeutics (OSIR): Q1 EPS of -$0.08 beats by $0.01. Revenue of $4.1M beats by $0.57M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Wednesday, March 6, 12:55 PM
Midday top 10 gainers: OSIR +30%. END +27%. HCI +19%. PCYG +18%. MERU +17%. EGLE +14%. MHH +14%. PRAN +13%. CYTR +13%. VGZ +13%.
Midday top 10 losers: OSH -17%. SCKT -14%. ACUR -12%. OSBC -11%. AEO -11%. AVAV -10%. VSCI -10%. TFM -10%. MFB -10%. MOC -9%. Comment! [On the Move] - Wednesday, March 6, 11:00 AM Midday top 10 gainers: END +30%. OSIR +29%. HCI +19%. REGI +13%. PRAN +12%. CTCM +12%. SHIP +12%. XRM +12%. AACC +12%. MHH +12%. Midday top 10 Losers: OSH -16%. AVAV -14%. ACUR -13%. OSBC -12%. MOC -11%. RWC -10%. TFM -10%. HIMX -10%. AEO -10%. MFB -10%. Comment!
- Wednesday, March 6, 10:17 AM Osiris Therapeutics (OSIR +30%) soars after the company easily beat the Street with a narrower Q4 loss and better revenues. The company posted Q4 loss of $0.08 per share, versus the consensus for a $0.15 loss. Revenues were $3.1M, nearly a fourfold increase from the prior year, and better than analysts estimates of $2.91M. Gross margin also grew to 70% compared to 58% in Q411. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, March 6, 8:09 AM Osiris Therapeutics (OSIR): Q4 EPS of -$0.08 beats by $0.07. Revenue of $3.1M beats by $0.2M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Thursday, December 20, 2012, 9:10 AM
Premarket gainers: ROMA +57%. NYX +40%. ELOQ +30%. RAD +16%. ILMN +9%. VVUS +8%. NDAQ +7%. ARRS +6%. ICE +6%. JBL +5%.
Losers: FOLD -44%. MDRX -16%. OSIR -10%. NBG -5%. BBBY -5%. 2 Comments [On the Move] -
Tuesday, July 3, 2012, 9:12 AM
Premarket gainers: NSPH +17%. MODL +9%. CNSL +7%. ATPG +6%.
Losers: CHTP -52%. OSIR -7%. Comment! [On the Move] - Tuesday, July 3, 2012, 8:39 AM The Street's Adam Feuerstein accuses Osiris Therapeutics of (OSIR) misleading investors about the results from a Phase II trial of its stem-cell treatment Prochymal in heart-attack patients. "The company claimed the study was a success. That's not true," Feuerstein declares. "Figuring out Osiris' deception wasn't that difficult." Shares -5.2% premarket. Comment! [Healthcare, On the Move]
- Monday, June 18, 2012, 1:48 PM Osiris Therapeutics (OSIR) surges another 12.9% following the approval in New Zealand last week of Prochymal, the company's stem-cell therapy for acute graft-vs-host disease in children who have undergone bone marrow transplants. (previous) 2 Comments [Healthcare, On the Move]
- Thursday, June 14, 2012, 1:29 PM Osiris Therapeutics (OSIR) +10.7% after it receives approval to market its stem cell therapy Prochymal in New Zealand for treating graft-vs-host disease ((GvHD)) in children, adding to Canadian approval last month. Prochymal is the first therapy approved for GvHD, which occurs when immune cells in transplanted bone marrow attack the recipient's body cells. Comment! [Healthcare, On the Move]
-
Wednesday, May 30, 2012, 9:05 AM
Premarket gainers: NEON +30%. OSIR +13%. ISR +5%.
Losers: PBY -22%. PWRD -11%. RIMM -11%. DRYS -7%. TTM -6%. 1 Comment [On the Move] - Wednesday, May 30, 2012, 9:03 AM Stem cell company Osiris Therapeutics (OSIR) +12.8% premarket after saying its Grafix treatments received pass-through status under Medicare's outpatient prospective payment system. The new codes will facilitate reimbursement when Grafix products are used to treat Medicare patients in hospital outpatient departments and ambulatory surgical centers. Comment! [Healthcare, On the Move]
-
Friday, May 18, 2012, 9:05 AM
Premarket gainers: WGO +21%. FFN +14%. QPSA +11%. OSIR +10%. FL +8%. CRM +7%. NBG +6%. YHOO +5%.
Losers: ADSK -9%. GSS -8%. Comment! [On the Move] - Thursday, May 17, 2012, 6:23 PM Osiris Therapeutics (OSIR) has received marketing approval from Health Canada to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease in children. The approval marks the first time a manufactured stem cell product has been given regulatory clearance and the first therapy approved for the disease. Shares +14% AH. Comment! [Healthcare, On the Move]
- Friday, February 10, 2012, 2:37 PM Osiris Therapeutics (OSIR -5.2%) slips after a flareup with Sanofi over a sudden termination on an agreement to develop and commercialize Genzyme. Also adding to today's negative sentiment is the decision of JPMorgan to drop coverage on the stock. Comment! [Healthcare, On the Move]
- Tuesday, August 24, 2010, 9:51 AM Stem cell stocks are under pressure after yesterday's ruling by a federal judge that blocks federal funding for research involving human embryonic stem cells. STEM -6.3%, GERN -3.8%, CYTX -3.6%, ASTM -3.3%, ATHX -2.8%, SGMO -1.4%, OSIR -0.6%. 2 Comments
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.